Clinical Trials
110 trialsDP-04
AstraZeneca
ELEPHAS-02
Elephas
MERLIN_001
SkylineDx
TraveraRTGx
Travera Inc
UK-EnBiRiM
Pierre Fabre Ltd
LEGIT_MC_EVCDA
AI Labs Group S.L
LegitHealth PH
AI Labs Group S.L
LegitHealthSAN
AI Labs Group S.L
Using an Artificial Intelligence Medical Device to Help Primary Care Practitioners Identify and Manage Skin Conditions (Tumor, Inflammatory, and Infectious Diseases) in Adult Patients at Pozuelo and Majadahonda Health Centers
AI Labs Group S.L
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection
Novartis
Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
Amgen
SCORE
Natera, Inc.
TavieSkin
Pierre Fabre Medicament
RPx
Replimune, Inc.
ELEPHAS-05
Elephas
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma
Pharmassist Ltd
LEAD Melanoma
Novartis
NEUTROFLOW
OncoHost Ltd.
A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)
Bristol-Myers Squibb
Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab
Bristol-Myers Squibb
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
PROPHETIC
OncoHost Ltd.
Skin Cancer
Nuvana Healthcare LTD
AIQ TRAQinform
AIQ Solutions
ORACLE
Guardant Health, Inc.
Pan-tumor MRD Study
Paradigm Health
NICO
Bristol-Myers Squibb
How Consistent is the Output of DERM, When Used to Assess Images of Potentially Cancerous Skin Lesions.
Skin Analytics Limited
Combi-EU
EuMelaReg gGmbH
OCEANMIST
Pfizer
PREFER
Labcorp Corporation of America Holdings, Inc
COMO
Pamgene International B.V.
BEGIN
BostonGene
A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings
Pfizer
An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia
Bristol-Myers Squibb
Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo
Momentum Data
ROOT
Taproot Health
DERM-SUCCESS
DermaSensor, Inc.
BESPOKE Study of ctDNA Guided Immunotherapy
Natera, Inc.
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Bristol-Myers Squibb
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Sanguine Biosciences
A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma
Bristol-Myers Squibb
Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Metastatic Melanoma Patients
Novartis
A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy
Bristol-Myers Squibb
Assessing Tissue Remodeling in the Skin Using SFI (Skin Fluorescence Imaging)
Orlucent, Inc
Investigating Participation Patterns Among Stage IV Melanoma Patients
Power Life Sciences Inc.
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Fate Therapeutics
Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma
Hoffmann-La Roche
Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study
Namida Lab
Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)
Novartis